Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients Meeting Abstract
| Authors: | Kowanetz, M.; Zou, W.; Shames, D.; Cummings, C.; Rizvi, N.; Spira, A.; Frampton, G.; Leveque, V.; Flynn, S.; Mocci, S.; Shankar, G.; Funke, R.; Ballinger, M.; Waterkamp, D.; Chen, D.; Sandler, A.; Hampton, G.; Amler, L.; Hegde, P.; Hellmann, M. |
| Abstract Title: | Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients |
| Meeting Title: | IASLC 17th World Conference on Lung Cancer |
| Keywords: | biomarkers; immunotherapy; nsclc; mutational load |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 12 |
| Issue: | 1 Suppl. |
| Meeting Dates: | 2016 Dec 4-7 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-01-01 |
| Start Page: | S321 |
| End Page: | S322 |
| Language: | English |
| ACCESSION: | WOS:000413055800327 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2016.11.343 |
| Notes: | Meeting Abstract: OA20.01 -- Source: Wos |
